The Basel-based Novartis group reports a strong operational performance in the first half of 2009, driven by its pharmaceuticals division.
This content was published on
1 minute
Novartis said net sales for the first six months were $20.3 billion (SFr21.87 billion), an increase of eight per cent in local currencies but a decline of two per cent in dollars over the comparable period last year.
Net income for the first half was down by 12 per cent at $4.02 billion.
Announcing its second-quarter results on Thursday, Novartis said its net profit from April to June fell ten per cent, hurt by the dollar’s strength against the euro.
It dropped to $2.04 billion from $2.25 billion a year earlier, in line with analysts’ expectations.
“I am pleased that our pharmaceuticals business continues to deliver double-digit underlying growth driven by the strong momentum of our recently launched products.
“Our pipeline continues to deliver a steady stream of innovative medicines.”
Novartis is aiming to produce and commercialise a vaccine against the A/H1N1 swine flu virus and expects clinical trials to begin in July.
You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Pharmaceuticals face recession health check
This content was published on
Profits leapt 25 per cent last year at Swiss giant Novartis while rival Roche forged ahead with its hostile bid for biotech firm Genentech despite a dip in results. But balance sheets alone do not tell the whole story. Pharmaceutical companies traditionally weather economic downturns better than other industries as health spending is considered a…
This content was published on
Net sales were up by nine per cent to $41.5 billion on accelerating growth in the Pharmaceuticals divisions as well as “important contributions” from the Vaccines and Diagnostics business and Consumer Health. “Thanks to successful innovation and a leading market position of our healthcare business portfolio, Novartis achieved a strong performance in 2008,” commented Novartis…
This content was published on
The drugmaker said in a statement on Tuesday that the price was $200 million less than previously announced, due to a dividend payment. The purchase is the first step in Novartis’ agreement to acquire a majority stake in American firm Alcon from Swiss food multinational Nestlé. The deal was announced in April. Novartis has the…
This content was published on
Viruses come in all shapes and sizes. Here’s a selection of some of the more dangerous ones lurking out there. (Thomas Kern, swissinfo.ch; pictures: CDC)
You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.